It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IRIX’s FA Score shows that 1 FA rating(s) are green while.
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DRIO’s TA Score shows that 4 TA indicator(s) are bullish while IRIX’s TA Score has 4 bullish TA indicator(s).
IRIX (@Medical Specialties) experienced а +21.58% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -4.23%. For the same industry, the average monthly price growth was -2.87%, and the average quarterly price growth was -6.14%.
IRIX is expected to report earnings on Mar 06, 2025.
Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
DRIO | IRIX | DRIO / IRIX | |
Capitalization | 40.6M | 48.4M | 84% |
EBITDA | -49.57M | -6.79M | 730% |
Gain YTD | -55.174 | -39.858 | 138% |
P/E Ratio | N/A | N/A | - |
Revenue | 23.5M | 56.4M | 42% |
Total Cash | 43.9M | 9.82M | 447% |
Total Debt | 29.9M | 1.26M | 2,375% |
DRIO | IRIX | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 59 | 84 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 19 Undervalued | 90 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 97 | |
PRICE GROWTH RATING 1..100 | 89 | 62 | |
P/E GROWTH RATING 1..100 | 100 | 1 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DRIO's Valuation (19) in the Medical Specialties industry is significantly better than the same rating for IRIX (90). This means that DRIO’s stock grew significantly faster than IRIX’s over the last 12 months.
DRIO's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as IRIX (100). This means that DRIO’s stock grew similarly to IRIX’s over the last 12 months.
DRIO's SMR Rating (96) in the Medical Specialties industry is in the same range as IRIX (97). This means that DRIO’s stock grew similarly to IRIX’s over the last 12 months.
IRIX's Price Growth Rating (62) in the Medical Specialties industry is in the same range as DRIO (89). This means that IRIX’s stock grew similarly to DRIO’s over the last 12 months.
IRIX's P/E Growth Rating (1) in the Medical Specialties industry is significantly better than the same rating for DRIO (100). This means that IRIX’s stock grew significantly faster than DRIO’s over the last 12 months.
DRIO | IRIX | |
---|---|---|
RSI ODDS (%) | 3 days ago88% | 3 days ago85% |
Stochastic ODDS (%) | 3 days ago85% | 3 days ago87% |
Momentum ODDS (%) | 3 days ago89% | 3 days ago83% |
MACD ODDS (%) | 6 days ago83% | 3 days ago76% |
TrendWeek ODDS (%) | 3 days ago88% | 3 days ago77% |
TrendMonth ODDS (%) | 3 days ago86% | 3 days ago76% |
Advances ODDS (%) | 11 days ago80% | 7 days ago75% |
Declines ODDS (%) | 3 days ago88% | 3 days ago81% |
BollingerBands ODDS (%) | 3 days ago90% | 3 days ago84% |
Aroon ODDS (%) | 3 days ago83% | 3 days ago83% |
A.I.dvisor indicates that over the last year, DRIO has been loosely correlated with TWST. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if DRIO jumps, then TWST could also see price increases.
Ticker / NAME | Correlation To DRIO | 1D Price Change % | ||
---|---|---|---|---|
DRIO | 100% | -4.35% | ||
TWST - DRIO | 34% Loosely correlated | -5.31% | ||
VCYT - DRIO | 28% Poorly correlated | -2.97% | ||
XWEL - DRIO | 28% Poorly correlated | -1.50% | ||
BNGO - DRIO | 28% Poorly correlated | -3.83% | ||
ILMN - DRIO | 27% Poorly correlated | -5.05% | ||
More |
A.I.dvisor tells us that IRIX and MDXH have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IRIX and MDXH's prices will move in lockstep.
Ticker / NAME | Correlation To IRIX | 1D Price Change % | ||
---|---|---|---|---|
IRIX | 100% | -4.52% | ||
MDXH - IRIX | 31% Poorly correlated | -6.29% | ||
CNTGF - IRIX | 28% Poorly correlated | -16.77% | ||
SNN - IRIX | 26% Poorly correlated | +1.01% | ||
DRIO - IRIX | 26% Poorly correlated | -4.35% | ||
CSTL - IRIX | 25% Poorly correlated | -8.86% | ||
More |